GlassScriptPhysician profile
Holly Donald
NPI 1902332703
$3,840.45
in general payments reported to CMS, 2019-2025
26 companies · $1,043 in 2025
The $1,043 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $820 · 2022: $522 · 2023: $900 · 2024: $555 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,498.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $500.62 | 2021-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $434.02 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $357.22 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $344.13 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $329.32 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $323.96 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $260.22 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.82 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.31 | 2021-2025 | Xifaxan |
| Daiichi Sankyo INC. | $134.67 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $130.07 | 2021-2023 | |
| Glaxosmithkline, LLC. | $106.51 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $97.33 | 2021-2023 | Verquvo, Steglujan, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $93.47 | 2022 | |
| Exact Sciences Corporation | $79.96 | 2023-2025 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $34.29 | 2025 | Novasure |
| Ibsa Pharma INC. | $31.59 | 2022-2024 | Tirosint, Licart |
| Dexcom, INC. | $23.65 | 2023 | Dexcom G6 Transmitter |
| Smith+Nephew, INC. | $19.66 | 2021 | |
| Astellas Pharma US INC | $16.69 | 2023 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $15.27 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $14.89 | 2025 | Uptravi, Opsumit |
| Amarin Pharma, INC. | $14.88 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.17 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.12 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $13.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Donald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.